Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22479770 | 0.81 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL19564951 | 0.78 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL12144940 | 0.78 | — | — | |
| SCHEMBL21468611 | 0.76 | ALDH1A1 (0.33) | ALDH1A1POLBMAPT | |
| SCHEMBL882160 | 0.75 | ALDH1A1 (0.40) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL7934757 | 0.75 | ALDH1A1 (0.40) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL10955234 | 0.73 | ALDH1A1 (0.42) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL13346809 | 0.72 | ALDH1A1 (0.41) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL24502636 | 0.71 | ALDH1A1 (0.38) | ALDH1A1POLBMAPTHTTGRIN2D | |
| SCHEMBL19564870 | 0.71 | ALDH1A1 (0.38) | ALDH1A1POLBMAPTHTTGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163513-A1 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | CELLECTAR BIOSCIENCES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163513-A1 | Phospholipid-Flavagline Conjugates and Methods of Using the Same for Targeted Cancer Therapy | PHOSPHO1, PLEC, PEBP1 | ALDH1A1 1686/4885POLB 4755/4885MAPT 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.